Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quarterlies Round-Up: Varian maintains progress as Rita Medical sees improvements

This article was originally published in Clinica

Executive Summary

Cholestech's first quarter revenues were negatively impacted by the company's decision, announced at the end of fiscal 2004, to eliminate quarter-end discounts for distributors that make large volume purchases. The Californian diagnostics developer believes that sales to its product distributors are now normalised with sales to end-users and expects revenue growth in excess of 10% for the remaining nine months of fiscal 2005. The company is also expecting a further boost to its cholesterol and diabetes franchises from January 2005 onwards, once the US Prescription Drug and Medicare Improvement Act of 2003 is implemented, and reimbursement for cholesterol and diabetes screening will be provided.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel